HDAC Inhibitors
The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
... Pan-HDAC inhibitors usually contain unwanted off- target effects limiting the clinical application unavoid- ably. Drug combination is a feasible strategy that could utilize the compensatory mechanisms and ...
6
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
... In a previous study, a JAK1-STAT3 signalling-centred feedback loop restrained the efficacy of traditional HDAC inhibitors in solid tumours. Increased STAT3 activity stimulates antiapoptotic signalling, ...
17
STEROIDAL HYDROXAMICACID DERIVATIVES: A STRUCTURALLY NOVEL CLASS OF HDAC INHIBITORS
... Accordingly, HDAC inhibitors are very promising chemotherapeutic agents capable of regulating gene expression, as well as proteins in pathways that regulate cell proliferation, cell migration, cell death ...
6
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
... with the recent discovery of BET bromodomain inhibitors such as JQ1 [25], I-BET151 [26], I-BET726 [27]. Previous studies in hematological malignancies have suggested that co-treatment with BET and HDAC ...
13
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
... various HDAC inhibitors can be combined experimentally, there are mixed reports of therapeutic efficacy relative to their synergistic ...because HDAC functions are complex, divergent, and redundant ...
9
Design, Synthesis and Anticancer Activity of Noval Piperidine Hydroxamate as HDAC Inhibitors.
... research. HDAC has majorly two types. Sub type (HDAC) 8 is more efficient target for hydroxymate ...as HDAC inhibitors with IC50 of micromolar ...
110
New and emerging HDAC inhibitors for cancer treatment
... of HDAC function (3). However, while a large number of nonhistone HDAC substrates have been identified, the molecular and biological consequences of nonhistone protein deacetylation is yet to be elucidated ...
11
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
... expression (Additional file 7: Figure S4). We extended this study to the mRNA expression of other CTA, MAGE-A1 (Fig. 3c), MAGE-A3 (Fig. 3d) and XAGE-1b (Fig. 3e). Globally, all HDACi increased CTA induced by decitabine. ...
11
Design, Synthesis and Anticancer Screening of Novel Piperidine ydroxamate as HDAC Inhibitors.
... research. HDAC has majorly two types. Sub type (HDAC) 8 is more efficient target for hydroxymate ...as HDAC inhibitors with IC50 of micromolar ...
105
HDAC inhibitors stimulate viral transcription by multiple mechanisms
... Characteristically, many genes which are responsive to HDAC inhibitors contain specific response elements such as Sp1/Sp3 binding sites [22]. In this regard it is interest- ing to note that the SV40 ...
11
Effects of novel HDAC inhibitors on urothelial carcinoma cells
... fects are similar, but, importantly, non-cancerous urothelial cells retain the potential for long-term growth, presumably by properly activating G1 checkpoints [20]. By comparison, immortalized HBLAK urothelial cells ...
18
HDAC INHIBITORS: A NEW ARMOUR IN ANTI-CANCER THERAPEUTICS
... Beyond cancer there may be several novel therapeutic areas where HDACi may provide therapeutic benefits. Early in the investigations on HDAC inhibitors it was recognized that one of the effects was the ...
10
Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV 1 latency
... A key objective of this study was to evaluate HERV expression following treatment with the HDAC inhibi- tors. Given the use of these drugs in the treatment of certain cancers and the reactivation of latent HIV-1, ...
11
The efficacy of HDAC inhibitors in neoplasm treatment
... of HDAC inhibitors in solid tumors has not been ...However, HDAC inhibitors in combination therapies have a growing high potential for use ...
7
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
... enzyme inhibitors like DNA-methyltransferase inhibitors or inhibitors of histone- modifying ...(HDAC) inhibitors are in clinical ...
20
The Therapeutic Potential of HDAC Inhibitors in the Treatment of Multiple Sclerosis
... is, inhibitors of HDACs might exert protection from the autoimmune response within the nervous system via both their immunosuppressing effects and their promotion of neuronal survival (see Figure ...
6
Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cells
... No increased genomic susceptibility to common anti- cancer drugs was found for normal breast (MCF-12) and intestinal epithelial cells (FHs 74 int) (Kim et al. 2003). Cell exposure to cisplatin, a DNA cross-linker, ...
10
Genes and epigenetic processes as prospective pain targets
... with HDAC activity can attenuate pain-related behavior in several preclinical infl ammatory pain models ...As HDAC inhibitors have been shown to have anti-infl ammatory properties in other models ...
10
Epigenetics in breast cancer: what's new?
... of HDAC inhibitors have been rationally designed and synthesized based on their chemical structures and divided into four groups: hydroxamic acids, cyclic tetrapeptides, short-chain fatty acids, and ...
11
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
... of 0.396 and 0.765. These results suggested that combin- ation of vorinostat or pracinostat with tozasertib synergis- tically enhanced the toxicities of these drugs in T315I positive Ba/F3 cells. Thus, we demonstrated ...
9